Dissertation > Excellent graduate degree dissertation topics show

Clinical and Experimental Study about Influence of Proton Pump Inhibitors on the Effectiveness of Clopidogrel

Author: YuQiong
Tutor: ZhangYu
School: Fudan University
Course: Geriatrics
Keywords: Proton pump inhibitors Clopidogrel Risk of cardiovascular Arterial thrombus Phosphorylation of vasodilator-stimulated phosphoprotein Platelet aggregation
CLC: R541.4
Type: Master's thesis
Year: 2011
Downloads: 28
Quote: 0
Read: Download Dissertation

Abstract


Objective:(1)To assess an association between use of proton-pump inhibitors (PPIs) in combination with clopidogrel and an increased risk of cardiovascular events in elder patients with acute coronary syndrome (ACS).(2)To investigate the influence of PPIs on the antithrombotic efficacy and antiplatelet action of clopidogrel in rat models of arterial thrombosis.Methods:(1)Retrospective cohort study of 109 patients with ACS taking clopidogel after discharge from Huashan Hospital between June,2007 and May,2010. They were assigned to case group with PPIs and control group without PPIs. Primary end points were the major adverse cardiac events(MACE) and second end points were all-cause mortality, rehospitalization for ACS,myocardial infarction, cardiac death, target vessel revascularization(TVR).We assessed the risk of adverse outcomes associated with concomitant use of clopidogrel and PPIs.(2) Sixty male Sprague-Dawley rats were randomly divided into six groups:concomitant use of clopidogrel and PPIs (omeprazole of high dose, omeprazole of low dose,esomeprazole, pantoprazole), use of clopidogrel without PPIs,normal control group. Rats model of carotid arterial thrombosis were induced by FeC13 Arterial thrombus weight,ADP induced platelet aggregation, phosphorylation of vasodilator-stimulated phosphoprotein(VASP) were measured to compare the influence of PPIs on the effectiveness of clopidogrel.Results:(1)There were no significant difference in the incidence of major adverse cardiac events(major adverse cardiac events) between patients with PPIs and without PPIs (36.7%vs.48.3%,P>0.05). Comparing the incidence of second end points in patients using clopidogrel alone,the incidence of all-cause mortality (4.1%vs.16.7%), rehospitalization for ACS (32.7%vs.38.3%),myocardial infarction (8.2%vs.20.0%), cardiac death (2.0%vs.6.7%),target vessel revascularization (4.1%vs.5.0%) in patients with concomitant use of clopidogrel and PPIs were not significantly different (P> 0.05). No association existed between PPIs use and risk of the primary end points for elderly treated with clopidogrel (AHR1.10,95%CI:0.56-2.19).Use of clopidogrel and PPIs was not associated with an increased risk of all-cause mortality (AHR0.49,95% CI:0.07-3.46), rehospitalization for ACS (AHR1.28,95%CI:0.62-2.65), myocardial infarction (AHR 0.59,95%CI:0.16-2.15), cardiac death (AHR0.39,95%CI:0.04-3.85), target vessel revascularization(AHR1.23,95%CI:0.17-8.70).(2)There was no statistical difference in thrombus weight,platelet aggregation and VASP-P between concomitant use of clopidogrel with PPIs (omeprazole, esomeprazole, pantoprazole) and use of clopidigrel without PPIs (P>0.05). Different PPIs in combination with clopidogrel had little variance among thrombus weight, platelet aggregation and VASP-P, but had not statistical difference (P>0.05).Different doses of omeprazole had no significant statistical difference in thrombus weight,platelet aggregation,VASP-P comparing with non-PPIs group (P>0.05).But thrombus weight, platelet aggregation, VASP-P in high dose of omeprazole were higher than in low dose of omeprazole (P<0.05).Conclusion:Co-administration of PPIs and clopidogrel would not increase the risk of cardiovascular events in elderly with ACS. Different PPIs had no influence on the antithrombotic efficacy and antiplatelet action of clopidogrel.PPIs could be used in combination with clopidogrel when clinically indicated, except high dose of omeprazole.

Related Dissertations

  1. CYP2C19 Gene Polymorphism in Patients with Ischemic Cerebrovascular,R743
  2. Synthesis and Development of Disodinum Clodronate、 Prasugrel and Pharmaceutical Intermediate,TQ463
  3. Research on Preparation of Clopidogrel Related Compound A and C and Clopidogrel Crystal Form and Diastereoisomeric Salt,TQ460.6
  4. Patients with coronary heart disease after interventional treatment of long-term dual antiplatelet efficacy and safety study,R541.4
  5. Risk Factors for Cerebral Microbleeds and the Relationship between Cerebral Microbleeds and Cognition Disorders in Patients with Ischemic Cerebrovascular Disease,R743.3
  6. Extraction, Purification and in Vitro Bioactivities of Resveratrol from Wine Dregs,TS261.9
  7. Analysis of acute coronary syndrome percutaneous coronary intervention in the clopidogrel resistance problem,R541.4
  8. Tirofiban hydrochloride clopidogrel resistance in patients with acute coronary syndrome, coronary interventional treatment efficacy and safety evaluation,R541.4
  9. Ionic contrast agent effects on human platelet aggregation studies,R541.7
  10. Poison damage of brain collateral \,R255.2
  11. Restructuring lampreys RGD peptides antithrombotic Pharmacodynamics,R285.5
  12. Synthesis of Prasugrel and the Analogs,R914
  13. Risk Factors of Clopidogrel Resistance and Impact of Different Proton Pump Inhibitors on the Antiplatelet Activity of Clopidogrel,R541.4
  14. Patients with cerebral infarction platelet - monocyte aggregates levels and stroke disease nature of the relationship between hormone,R277.7
  15. Design, Synthesis and Bioactivity Studies of Novel Ligustrazine Derivatives,R284
  16. Real-world Study for Different Clopidogrel Loading Doses on Platelet Function in Patients with Acute Coronary Syndrome,R541.4
  17. Elderly patients with coronary heart disease different types of antiplatelet drugs in clinical studies,R541.4
  18. Studies on the Synthesis, Activity of Thieno [3, 2-c] Pyridine Hydrazide Derivatives and Its Metabolism in Vitro,R914
  19. The Prevalence and Influential Factors of Clopidogrel Resistance in Patients with Acute Coronary Syndrome,R541.4
  20. Clinical Study of Effect of Atorvastatin on the Antiplatelet Functions of Clopidogrel and Combined Effect with COQ10 on Liver Enzyme Activity and Lipid Levels,R541.4

CLC: > Medicine, health > Internal Medicine > Heart, blood vessels ( circulatory ) disease > Heart disease > Coronary arteries ( atherosclerosis ),heart disease (CHD)
© 2012 www.DissertationTopic.Net  Mobile